FDA-cleared profile

syngo.via MI Workflows; Scenium; syngo MBF

Siemens Medical Solutions USA, Inc. · PET/SPECT/Nuclear Medicine · FDA-cleared (510(k))

Authorized purpose: syngo.via MI Workflows VB80A, Scenium VE60, and syngo MBF VB30 support PET, SPECT, nuclear-medicine, CT, and MR viewing, quantification, analysis, longitudinal comparison, organ segmentation, tumor-burden assessment, tau analysis, myocardial blood-flow analysis, and selected radiotherapy-planning support.

Clinical role
Multimodality molecular-imaging post-processing and quantitative review for oncology, cardiology, neurology, organ function, and selected treatment-planning workflows.
Images and patients
PET/SPECT/Nuclear Medicine · Multi-region
Key limitation
Keep in mind: Clinical testing was not conducted for this submission. The packet identifies accuracy and calibration of the CT scanner, image reconstruction settings, contrast amount and injection protocol, scan protocol and dose, patient compliance, patient anatomy, organ size, patient orientation and position, and user skills as factors known to affect segmentation accuracy.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: syngo.via MI Workflows VB80A, Scenium VE60, and syngo MBF VB30 support PET, SPECT, nuclear-medicine, CT, and MR viewing, quantification, analysis, longitudinal comparison, organ segmentation, tumor-burden assessment, tau analysis, myocardial blood-flow analysis, and selected radiotherapy-planning support.
  • Which images or clinical context are in scope?Modality: PET/SPECT/Nuclear Medicine Anatomy or clinical context: Multi-region Input: PET or nuclear-medicine functional data plus optional CT or MR anatomical datasets from one or more time points.
  • Who uses it?Intended users: Reading physicians, radiologists, nuclear-medicine technologists, and other appropriately trained healthcare professionals.
  • What does the software produce?Output: Viewing, manipulation, quantification, analysis and comparison of PET/NM and CT/MR images; harmonized PET SUV values; organ segmentation and organ-specific tumor-burden features; and tau PET quantification with cortical and background SUVR calculations.
  • What is its most important limitation?Key limitation: Clinical testing was not conducted for this submission. The packet identifies accuracy and calibration of the CT scanner, image reconstruction settings, contrast amount and injection protocol, scan protocol and dose, patient compliance, patient anatomy, organ size, patient orientation and position, and user skills as factors known to affect segmentation accuracy.

Clinical takeaway. Clinical role: syngo.via MI Workflows VB80A, Scenium VE60, and syngo MBF VB30 support PET, SPECT, nuclear-medicine, CT, and MR viewing, quantification, analysis, longitudinal comparison, organ segmentation, tumor-burden assessment, tau analysis, myocardial blood-flow analysis, and selected radiotherapy-planning support.

Evidence takeaway. Evidence from the reviewed source record: K232000 reports software verification, quantitative organ-segmentation testing, and agreement testing for tau quantification. All organs met either Dice or average symmetric surface-distance criteria, and tau SUVR comparisons on more than 700 ADNI flortaucipir images showed good correlation and agreement with an MR-based method; no clinical study was performed.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
syngo.via MI Workflows VB80A, Scenium VE60, and syngo MBF VB30 support PET, SPECT, nuclear-medicine, CT, and MR viewing, quantification, analysis, longitudinal comparison, organ segmentation, tumor-burden assessment, tau analysis, myocardial blood-flow analysis, and selected radiotherapy-planning support.
  • Exact FDA submission
  • Checked 2026-09-19

Clinical-use display mirrors the exact FDA-supported purpose reconciled from the decision-summary packet.

Workflow role
Multimodality molecular-imaging post-processing and quantitative review for oncology, cardiology, neurology, organ function, and selected treatment-planning workflows.
  • Exact FDA submission
  • Checked 2026-09-03
Required input
PET or nuclear-medicine functional data plus optional CT or MR anatomical datasets from one or more time points.
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Output and clinician action
Viewing, manipulation, quantification, analysis and comparison of PET/NM and CT/MR images; harmonized PET SUV values; organ segmentation and organ-specific tumor-burden features; and tau PET quantification with cortical and background SUVR calculations.
  • Exact FDA submission
  • Checked 2026-09-19

The exact packet supports these outputs and does not expose a myocardial-blood-flow result description.

Care setting
Hospital and outpatient molecular-imaging reading environments using the syngo.via client/server platform.
  • Exact FDA submission
  • Checked 2026-09-03
Intended users
Reading physicians, radiologists, nuclear-medicine technologists, and other appropriately trained healthcare professionals.
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Limitations
Clinical testing was not conducted for this submission. The packet identifies accuracy and calibration of the CT scanner, image reconstruction settings, contrast amount and injection protocol, scan protocol and dose, patient compliance, patient anatomy, organ size, patient orientation and position, and user skills as factors known to affect segmentation accuracy.
  • Exact FDA submission
  • Checked 2026-09-19

The replacement uses the exact packet's clinical-testing statement and listed segmentation-accuracy factors and removes the unsupported blanket professional-review sentence.

Evidence summary
K232000 reports software verification, quantitative organ-segmentation testing, and agreement testing for tau quantification. All organs met either Dice or average symmetric surface-distance criteria, and tau SUVR comparisons on more than 700 ADNI flortaucipir images showed good correlation and agreement with an MR-based method; no clinical study was performed.
  • Exact FDA submission
  • Checked 2026-09-03

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
K232000 reports software verification, quantitative organ-segmentation testing, and agreement testing for tau quantification. All organs met either Dice or average symmetric surface-distance criteria, and tau SUVR comparisons on more than 700 ADNI flortaucipir images showed good correlation and agreement with an MR-based method; no clinical study was performed.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-03
Reported sensitivity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-03

Sensitivity is not the primary applicable endpoint for this acquisition, reconstruction, segmentation, planning, guidance, or quantitative-biomarker function. Use the task-specific endpoints and tested population reported below.

Reported specificity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-03

Specificity is not the primary applicable endpoint for this acquisition, reconstruction, segmentation, planning, guidance, or quantitative-biomarker function. Use the task-specific endpoints and tested population reported below.

Tau workflow comparison images

700 images

  • EndpointFlortaucipir SUVR agreement against an MR-based method
  • Populationsyngo.via MI Workflows; Scenium; syngo MBF
  • Tested versionsyngo.via MI Workflows VB80A, Scenium VE60, and syngo MBF VB30

K232000 FDA performance package for syngo.via MI Workflows; Scenium; syngo MBF

  • DesignManufacturer nonclinical software verification plus organ-segmentation and tau-quantification agreement testing
  • PopulationRepresentative molecular-imaging datasets, including more than 700 ADNI flortaucipir PET images for the tau workflow
  • Scopeexact submission
  • Tested versionsyngo.via MI Workflows VB80A, Scenium VE60, and syngo MBF VB30
  • IndependenceSponsor or vendor study

K232000

Manufacturer evidence submitted for substantial equivalence; local clinical, technical, and workflow acceptance remains necessary.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K232000 by exact submission identifier.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-03

A zero-result exact-identifier search does not prove that no recall, correction, adverse-event report, or product-family safety signal exists.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the device within the applicable imaging or surgical service line and verify payer, site-of-service, and coding assumptions independently.
  • Service-level, not product-specific
  • Checked 2026-09-03

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

Build a local total-cost and value model; do not infer reimbursement from FDA clearance.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: PET or nuclear-medicine functional data plus optional CT or MR anatomical datasets from one or more time points.

    Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-19 · FDA K232000: syngo.via MI Workflows; Scenium; syngo MBF

  2. Routing

    Source context, not route validation: DICOM transfers into a syngo.via server/client environment with configurable automatic import, manual media import, reporting, and storage; validate PET/SPECT/CT/MR objects, SUV harmonization, time points, output routing, and OpenApps launch behavior.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-03 · FDA K232000: syngo.via MI Workflows; Scenium; syngo MBF · syngo.via molecular imaging reading software

  3. AI processing

    Source context, not route validation: Software-only applications installed on common IT hardware as part of the syngo.via client/server system; exact licenses and supported platform versions must be mapped locally.

    Scope: Exact FDA submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-03 · FDA K232000: syngo.via MI Workflows; Scenium; syngo MBF · syngo.via molecular imaging reading software

  4. Returned objects

    Source context, not route validation: Viewing, manipulation, quantification, analysis and comparison of PET/NM and CT/MR images; harmonized PET SUV values; organ segmentation and organ-specific tumor-burden features; and tau PET quantification with cortical and background SUVR calculations.

    Scope: Exact FDA submission. The exact packet supports these outputs and does not expose a myocardial-blood-flow result description.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-19 · FDA K232000: syngo.via MI Workflows; Scenium; syngo MBF

  5. Viewer/worklist/report

    Unresolved route: Viewing, manipulation, quantification, analysis and comparison of PET/NM and CT/MR images; harmonized PET SUV values; organ segmentation and organ-specific tumor-burden features; and tau PET quantification with cortical and background SUVR calculations.

    Scope: Exact FDA submission. The exact packet supports these outputs and does not expose a myocardial-blood-flow result description.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-19 · FDA K232000: syngo.via MI Workflows; Scenium; syngo MBF

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
Software-only applications installed on common IT hardware as part of the syngo.via client/server system; exact licenses and supported platform versions must be mapped locally.
  • Exact FDA submission
  • Checked 2026-09-03
Integration
DICOM transfers into a syngo.via server/client environment with configurable automatic import, manual media import, reporting, and storage; validate PET/SPECT/CT/MR objects, SUV harmonization, time points, output routing, and OpenApps launch behavior.
  • Exact FDA submission
  • Checked 2026-09-03
Security
Siemens Healthineers' corporate cybersecurity page states a Secure Development Lifecycle addressing pre-market and post-market phases for products under development and a range of existing offerings; a Cybersecurity Management Service maintaining a product security inventory (over 1,000 product versions and over 21,000 monitored software components) with security whitepapers, SBOMs and vulnerability assessments available to customers via teamplay Fleet; incident and vulnerability management channels; and that Siemens Healthineers AG maintains an independent certification of its global Cybersecurity Management System to ISO/IEC 27001:2022 extended by ISO/IEC 27701:2019, with the certificate referenced to the SGS directory. Vendor statement; no certificate or report was read.
  • Vendor-wide
  • Checked 2026-10-26

Vendor statement, not an attestation. Identity bridge: Siemens Healthineers' own corporate-info page names Siemens Medical Solutions USA, Inc. (Malvern, PA), and its 2024 governance press release states Siemens Healthcare GmbH's business was transferred to Siemens Healthineers AG. Corporate program statement; exact-release scope is not established.

Training
Only reading physicians, radiologists, nuclear-medicine technologists, and other appropriately trained healthcare professionals. should operate or interpret the system. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
  • Exact FDA submission
  • Checked 2026-09-03
Monitoring
Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track the limits that matter for this product: Clinical testing was not conducted for K232000. Segmentation can be affected by scanner calibration, reconstruction, contrast protocol, dose, motion, anatomy, organ size, orientation, and user skill; all quantitative outputs require professional review.
  • Exact FDA submission
  • Checked 2026-09-03

Release and scope verification

Map the installed model, build, options, population, anatomy, inputs, and outputs to K232000 before acceptance.

exact submission · checked 2026-09-03

Later product-family features are not evidence that this cleared release includes them.

Interoperability acceptance

DICOM transfers into a syngo.via server/client environment with configurable automatic import, manual media import, reporting, and storage; validate PET/SPECT/CT/MR objects, SUV harmonization, time points, output routing, and OpenApps launch behavior.

exact submission · checked 2026-09-03

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Clinical testing was not conducted for K232000. Segmentation can be affected by scanner calibration, reconstruction, contrast protocol, dose, motion, anatomy, organ size, orientation, and user skill; all quantitative outputs require professional review.

exact submission · checked 2026-09-03

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.

product family · checked 2026-09-03

Vendor productivity claims are scenario inputs, not guaranteed local savings.

Lifecycle monitoring

Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track the limits that matter for this product: Clinical testing was not conducted for K232000. Segmentation can be affected by scanner calibration, reconstruction, contrast protocol, dose, motion, anatomy, organ size, orientation, and user skill; all quantitative outputs require professional review.

exact submission · checked 2026-09-03

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K232000
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
PET/SPECT/Nuclear Medicine
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Anatomy
Multi-region
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2023-11-28
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
27Fields reviewed
11Source classes checked
18Screened PubMed leads
2Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains 18 PubMed and 2 ClinicalTrials.gov candidate records. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 18 PubMed and 2 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, vendor product page, reimbursement policy, fda device recall, fda decision summary packet, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-03 - Exact FDA submission

    No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, enabled features, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed

8 sources - 3 history items

Source ledger

  1. FDA K232000: syngo.via MI Workflows; Scenium; syngo MBF

    U.S. Food and Drug Administration - Published 2023-11-28 - Accessed 2026-09-19

    Scope: modality, anatomy, intendedUsers, input, evidenceSummary, purpose, output, limitations, clinicalUse

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  4. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  5. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. syngo.via molecular imaging reading software

    Siemens Healthineers - Accessed 2026-09-03

    Scope: productFamily, workflowRole, integration, deployment, implementationCapabilities, currentCommercialContext

  8. Siemens Healthineers: Cybersecurity

    Siemens Healthineers - Accessed 2026-10-26

    Scope: security

Research history

  1. K232000 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K251528

syngo.via MI Workflows; Scenium; syngo MBF

Siemens Medical Solutions USA, Inc.

Authorized purpose: syngo.via MI Workflows, Scenium, and syngo MBF provide PET, SPECT, nuclear-medicine, CT, and MR viewing, manipulation, quantification, longitudinal comparison, and analysis for oncology, cardiology, neurology, organ function, and selected radiation-planning support.

Modality
PET/SPECT/Nuclear Medicine
Anatomy
Multi-region
Decision
2025-07-03
FDA-cleared K242275

syngo.via MI Workflows; Scenium; syngo MBF

Siemens Medical Solutions USA, Inc.

Authorized purpose: syngo.via MI Workflows, Scenium, and syngo MBF are medical diagnostic post-processing applications for viewing, manipulation, quantification, analysis, and comparison of PET or nuclear-medicine functional data with CT or MR anatomical data across timepoints, supporting disease management and radiotherapy treatment planning by trained healthcare professionals.

Modality
PET/SPECT/Nuclear Medicine
Anatomy
Multi-region
Decision
2024-08-30
FDA-cleared K232712

uMI Panorama

Shanghai United Imaging Healthcare Co., Ltd.

Authorized purpose: uMI Panorama combines PET and CT to provide quantitative radiopharmaceutical distribution, diagnostic anatomical and attenuation information, and fused PET/CT images for qualified healthcare professionals supporting detection, localization, diagnosis, staging, restaging, treatment planning, and treatment-response evaluation across oncology, cardiology, neurology, and other disorders; its CT subsystem can also perform standalone diagnostic imaging and protocol-governed low-dose lung cancer screening.

Modality
PET/SPECT/Nuclear Medicine
Anatomy
Multi-region
Decision
2023-10-03
FDA-cleared K231572

uMI Panorama

Shanghai United Imaging Healthcare Co., Ltd.

Authorized purpose: uMI Panorama GS combines 148 cm axial-field-of-view PET with CT to provide quantitative radiopharmaceutical distribution, diagnostic anatomical and attenuation information, and registered or fused PET/CT images supporting detection, localization, diagnosis, staging, restaging, treatment planning, and treatment-response evaluation in oncology, cardiology, neurology, inflammation, infection, and other disorders. The CT subsystem can also perform standalone diagnostic imaging and protocol-governed low-dose lung cancer screening.

Modality
PET/SPECT/Nuclear Medicine
Anatomy
Multi-region
Decision
2023-07-26

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history